EUVIMEDEUVIMED entdecken
Fallbericht

PCSK9 inhibitor use during pregnancy in a case of familial hypercholesterolemia complicated with coronary artery disease

Takuma Suzuki iD, Kotoi Tsurane, Tomoyuki Umemoto, Tetsuo Sasano, Eiko Ushiki, Ayako Fudono, Asuka Hirose, Masaki Sekiguchi, Naoyuki Miyasaka

Journal of Obstetrics and Gynaecology Research · 2024

DOI: 10.1111/jog.15813 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2024. Verfasst von Takuma Suzuki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tokyo Medical and Dental University, Perinatal and Women's Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Coronary Artery Disease, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Grants-in-Aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited data have been reported on the use of proprotein convertase subtilisin/kexin type 9 (PCSK 9) inhibitors during pregnancy in women with familial hypercholesterolemia (FH). Here, we present the first case of initiating evolocumab (PCSK9 inhibitor) in a compound heterozygous FH mother. The patient was a 34‐year‐old primipara with severe dyslipidemia and a history of coronary artery bypass surgery. An elevated low‐density lipoprotein cholesterol (LDL‐C) level of 420 mg/dL was detected in the first trimester and persistently increased throughout pregnancy. Evolocumab was administered at 31 and 35 weeks of gestation, showing a positive effect on stabilizing LDL‐C levels. Planned delivery with labor analgesia was performed at 38 + 4 weeks. Both the mother and infant were discharged without any notable complications. Hence, evolocumab, an IgG2 monochromatic antibody with little placental permeability, may be an alternative medication with limited influence on infants. Further studies are needed to assess the safety of evolocumab administration during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseHyperlipoproteinemia Type IIPregnancyFemaleHumansAdultCholesterol, LDLPCSK9 InhibitorsProprotein Convertase 9Antibodies, MonoclonalPlacenta

Stichwörter der Autor:innen

PCSK9 inhibitorevolocumabfamilial hypercholesterolemialipoprotein apheresispregnancy

Substanzen

Cholesterol, LDLPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Antibodies, Monoclonal

Autor:innen und Institutionen

  • Tokyo Medical and Dental University, Perinatal and Women's Medicine, Tokyo, Japan.
  • Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

ORCID-Profile: Takuma Suzuki

Förderung

  • Grants-in-Aid for Scientific Research

Zitieren

APA

Suzuki, T., Tsurane, K., Umemoto, T., Sasano, T., Ushiki, E., Fudono, A., Hirose, A., Sekiguchi, M., & Miyasaka, N. (2024). PCSK9 inhibitor use during pregnancy in a case of familial hypercholesterolemia complicated with coronary artery disease. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15813

Vancouver

Suzuki T, Tsurane K, Umemoto T, Sasano T, Ushiki E, Fudono A, et al. PCSK9 inhibitor use during pregnancy in a case of familial hypercholesterolemia complicated with coronary artery disease. Journal of Obstetrics and Gynaecology Research. 2024. doi:10.1111/jog.15813

BibTeX
@article{Suzuki2024,
  author = {Suzuki, Takuma and Tsurane, Kotoi and Umemoto, Tomoyuki and Sasano, Tetsuo and Ushiki, Eiko and Fudono, Ayako and Hirose, Asuka and Sekiguchi, Masaki and Miyasaka, Naoyuki},
  title = {PCSK9 inhibitor use during pregnancy in a case of familial hypercholesterolemia complicated with coronary artery disease},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2024},
  doi = {10.1111/jog.15813}
}
Kostenlos starten →